Compare GXO & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GXO | BLTE |
|---|---|---|
| Founded | 2021 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 6.2B |
| IPO Year | 2021 | 2021 |
| Metric | GXO | BLTE |
|---|---|---|
| Price | $48.45 | $145.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 7 |
| Target Price | $67.91 | ★ $198.00 |
| AVG Volume (30 Days) | ★ 1.1M | 220.9K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $13,178,000,000.00 | N/A |
| Revenue This Year | $6.81 | N/A |
| Revenue Next Year | $5.95 | $492.11 |
| P/E Ratio | $1,615.67 | ★ N/A |
| Revenue Growth | ★ 12.55 | N/A |
| 52 Week Low | $45.40 | $56.68 |
| 52 Week High | $66.85 | $200.00 |
| Indicator | GXO | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 45.73 | 51.32 |
| Support Level | $48.58 | $132.50 |
| Resistance Level | $55.55 | $168.44 |
| Average True Range (ATR) | 1.39 | 8.50 |
| MACD | 0.13 | 1.35 |
| Stochastic Oscillator | 24.16 | 73.31 |
GXO Logistics Inc is a contract logistics company. Its revenue is diversified across numerous verticals and customers, including many multinational corporations. It provides warehousing and distribution, order fulfillment, e-commerce, reverse logistics, and other supply chain services differentiated by its ability to deliver technology-enabled, customized solutions at scale. Geographically, it generates revenue from the United Kingdom, the United States, the Netherlands, France, Spain, Italy, and other countries, and derives the majority of its revenue from the United Kingdom.
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.